Israel is expected to sign a deal worth hundreds of millions of dollars with California-based Arcturus, which is currently in the advanced stages of testing a coronavirus vaccine, Health Minister Yuli Edelstein announced Thursday. The company, which would be the second vaccine creator Israel signs to follow Moderna, has already had successful animal testing and is moving to human testing and will receive funding from Israel according to the success levels of the various stages. test. If the company manages to produce a successful vaccine, it will provide Israel with four million. The Singapore Health Sciences Authority approved clinical trials for the vaccine, to be tested at the Duke-NUS School of Medicine in Singapore, on Wednesday, after which the company announced that it plans to enter those human trials soon as possible. Moon-COV19, the vaccine developed by Arcturus, is designed to potentially produce a single-dose and single-dose vaccine. The Duke-NUS team has worked with coronaviruses in the past, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Arcturus has partial roots in Israel as it merged with Alcobara Ltd. from Israel in 2017. And usually focuses on creating treatments for rare diseases and vaccines. Approximately 108 adults will participate in the vaccine trials, according to CNBC. According to the World Health Organization, there are more than 140 candidate vaccines in preclinical evaluation status worldwide and 24 in clinical evaluation.Maayan Jaffe-Hoffman contributed to this report.
